Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial

Jingxin Li1,2,10, Lihua Hou3,10, Xiling Guo1,10, Pengfei Jin1,10, Shipo Wu1,2,9, Jiahong Zhu4, Hongxing Pan1, Xue Wang5, Zhizhou Song4, Jingxuan Wan5, Lunbiao Cui1, Junqiang Li5, Yin Chen1, Xuewen Wang6, Lairun Jin7, Jingxian Liu1, Fungjuan Shi1, Xiaoyu Xu8, Tao Zhu5, Wei Chen3 and Fengcai Zhu1,2,9

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning of vaccine-elicited neutralizing antibodies suggests that additional coronavirus disease 2019 (COVID-19) vaccine doses may be needed for individuals who initially received CoronaVac. We evaluated the safety and immunogenicity of the recombinant adenovirus type 5 (AD5)-vectored COVID-19 vaccine Convidecia as a heterologous booster versus those of CoronaVac as homologous booster in adults previously vaccinated with CoronaVac in an ongoing, randomized, observer-blinded, parallel-controlled phase 4 trial (NCT04892459). Adults who had received two doses of CoronaVac in the past 3–6 months were vaccinated with Convidecia (N = 96) or CoronaVac (N = 102). Adults who had received one dose of CoronaVac in the past 1–3 months were also vaccinated with Convidecia (N = 51) or CoronaVac (N = 50). The co-primary endpoints were the occurrence of adverse reactions within 28 d after vaccination and geometric mean titers (GMTs) of neutralizing antibodies against live wild-type SARS-CoV-2 virus at 14 d after booster vaccination. Adverse reactions after vaccination were significantly more frequent in Convidecia recipients but were generally mild to moderate in all treatment groups. Heterologous boosting with Convidecia elicited significantly increased GMTs of neutralizing antibody against SARS-CoV-2 than homologous boosting with CoronaVac in participants who had previously received one or two doses of CoronaVac. These data suggest that heterologous boosting with Convidecia following initial vaccination with CoronaVac is safe and more immunogenic than homologous boosting.

Effective COVID-19 vaccines are crucial for controlling the SARS-CoV-2 pandemic. In March 2021, China launched a national mass vaccination campaign with China National Medical Products Administration-authorized inactivated COVID-19 vaccines and a recombinant adenoaviruse type 5-vectored COVID-19 vaccine Convidecia (AD5-nCOV). In phase 3 trials, the two-dose regimen of the inactivated COVID-19 vaccine CoronaVac showed 50.4% vaccine effectiveness against symptomatic COVID-19 disease in Brazil, and one shot of Convidecia had 57.5% vaccine effectiveness in preventing symptomatic disease. To date, more than 2 billion doses of COVID-19 vaccines have been administered in mainland China alone, and over 50% of these were CoronaVac.

The two-dose regimen of CoronaVac has been deployed globally in 39 countries, including Brazil, Malaysia, Mexico, Pakistan, Chile, Egypt, Indonesia, Nepal and Turkey. The one-shot regimen of Convidecia has been authorized for use in eight countries, including China, Malaysia, Mexico, Pakistan, Chile, Ecuador, Argentina and Hungary. However, there is concern about the relatively lower immunogenicity and efficacy of inactivated COVID-19 vaccines compared with those of some other COVID-19 vaccines, such as BNT162b2. The emergence of SARS-CoV-2 variants with increased infectivity and transmissibility and the waning of neutralizing antibodies elicited by the inactivated vaccine might lead to lower vaccine protection.

A recently published trial with a homologous CoronaVac prime-boost regimen demonstrated a strong and rapid immune response elicited by the third dose, and the neutralizing antibody titer was three to fivefold higher than that after the authorized two-dose regimen. A study of homologous Convidecia prime-boosting in healthy participants showed a limited 1.7-fold increase in neutralizing antibody titer 56 d after the second dose of Convidecia, which may be inhibited by high titers of pre-existing neutralizing antibodies against the vector.

Heterologous schedules incorporating COVID-19 vaccines across different platforms may promote antibody affinity maturation and influence the breadth of vaccine-elicited neutralizing antibodies by including different antigens, types of vectors, delivery routes, doses and/or adjuvants at different times. The combination of heterologous prime-boost schedules with inactivated vaccines and adenoavirus-based vaccines such as AD5-nCOV, ChAdOx1 nCoV-19 or Ad26.COV2.S could also potentially enhance the feasibility of vaccine distribution, particularly for some low- or middle-resource countries with limited or unpredictable CoronaVac supplies to allow for three doses per individual. Here we report the safety and immunogenicity of initial vaccination with one or two doses of...
CoronaVac followed by heterologous boosting with Convidecia in Chinese adults in a prospective phase 4 trial (NCT04892459).

**Results**

**Study design and analysis set.** Between May 25 and 26, 2021, we recruited 302 participants aged between 18 and 75 years who had received one dose of CoronaVac in the past 1–3 months or two doses of CoronaVac in the past 3–6 months. Individuals with a previous COVID-19 diagnosis or confirmed SARS-CoV-2 infection and pregnant women were excluded from this study (Methods). A total of 300 participants were enrolled. Two hundred participants primed with two doses of CoronaVac (separated by an interval of 14–21 d) were included in the three-dose regimen cohort, and 100 participants primed with one dose of CoronaVac were included in the two-dose regimen cohort. Participants in the three-dose regimen cohort were randomized at a 1:1 ratio to receive a third dose of Convidecia (group A, heterologous booster dose, n = 100) or CoronaVac (group B, homologous booster dose, n = 100). Participants in the two-dose regimen cohort were randomized equally to receive a second dose of Convidecia (group C, heterologous dose, n = 50) or CoronaVac (group D, homologous dose, n = 50) (Fig. 1). A total of 299 participants who received a booster were included in the safety analysis (one participant withdrew before receiving their booster). The primary analysis was performed based on the intervention modified intention-to-treat cohort, adjusting the grouping of the 299 participants according to their actual vaccine allocations. One participant who only received one dose of CoronaVac but was randomized to receive a heterologous booster dose of Convidecia in group A was reclassified into group C. Two participants who were randomized to group A but were incorrectly given a homologous booster dose of CoronaVac were reclassified into group B.

There were two co-primary endpoints. The occurrence of adverse reactions within 28d after boosting was evaluated as the primary endpoint for safety, while the GMT of neutralizing antibodies against live SARS-CoV-2 virus at 14 d after boosting was the primary immunogenic endpoint. Incidence of solicited adverse reactions within 14 d, unsolicited adverse reactions within 28 d after boosting and serious adverse events reported during the 6-month study period were evaluated as secondary endpoints. Solicited adverse events were recorded by using a structured checklist in the participant diary card, while unsolicited adverse events were collected spontaneously (Methods). Receptor-binding domain (RBD)- and nucleocapsid (N)-specific immunoglobulin G (IgG) antibody responses at days 14 and 28 and T cell-secreted cytokines at day 14 after boosting were also evaluated as secondary endpoints. Neutralizing antibody titers against the Delta variant B.1.617.2 (live virus) and levels of IgG isotypes were measured as exploratory endpoints. The analysis of vaccine-induced antibody lineage development and B cell and T cell repertoires after vaccination are planned in the study protocol but are not completed yet. Here we report all collected data up to day 28 after vaccination.

In total, 299 participants received a booster dose on day 0 and completed 28 d of follow-up to assess safety. We obtained serum samples from 299 participants on day 0, from 298 participants on day 14 and from 293 participants on day 28. Demographic characteristics of participants across the groups were comparable (Table 1). At enrollment and before receiving a vaccine booster, the proportion of participants who had serum neutralizing antibodies against SARS-CoV-2 was higher in group A than that in group B (27.1% versus 11.8%, P value = 0.0062) but similar between group C and group D.
Table 1 | Baseline characteristics of participants in the modified full-analysis cohort

|                          | Group A (two doses primed + Convidecia, n = 96) | Group B (two doses primed + CoronaVac, n = 102) | Group C (one dose primed + Convidecia, n = 51) | Group D (one dose primed + CoronaVac, n = 50) |
|--------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Age in years (%)         |                                               |                                               |                                               |                                               |
| 18–50                    | 67 (69.8)                                     | 69 (67.7)                                     | 37 (72.6)                                     | 39 (78.0)                                     |
| 51–59                    | 29 (30.2)                                     | 33 (32.4)                                     | 14 (27.5)                                     | 11 (22.0)                                     |
| Median age (IQR)         | 470 (40.3, 51.0)                              | 470 (41.0, 52.0)                              | 470 (35.0, 51.0)                              | 43.5 (38.5, 49.3)                             |
| Sex (%)                  |                                               |                                               |                                               |                                               |
| Male                     | 58 (60.4)                                     | 64 (62.8)                                     | 27 (52.9)                                     | 30 (60.0)                                     |
| Female                   | 38 (39.6)                                     | 38 (37.3)                                     | 24 (47.1)                                     | 20 (40.0)                                     |
| Baseline neutralizing antibody against SARS-CoV-2 (%)<sup>a</sup> |                                               |                                               |                                               |                                               |
| Negative                 | 70 (72.9)                                     | 90 (88.2)                                     | 48 (94.1)                                     | 48 (96.0)                                     |
| Positive                 | 26 (27.1)                                     | 12 (11.8)                                     | 3 (5.9)                                       | 2 (4.0)                                       |
| Ethnicity                |                                               |                                               |                                               |                                               |
| Han                      | 96 (100)                                      | 102 (100)                                     | 51 (100)                                      | 50 (100)                                      |
| Time since the last priming dose of inactivated vaccine (months) |                                               |                                               |                                               |                                               |
| Median (IQR)             | 3.2 (3.2, 4.6)                                | 3.3 (3.2, 4.6)                                | 1.8 (1.8, 1.8)                                | 1.8 (1.8, 1.8)                                |
| Pre-existing AD5-neutralizing antibodies (%) |                                               |                                               |                                               |                                               |
| Participants with titer ≤1:200 | 27 (28.1)                                     | 38 (37.3)                                     | 19 (37.3)                                     | 15 (30.0)                                     |
| Participants with titer >1:200 | 69 (71.9)                                     | 64 (62.7)                                     | 32 (62.7)                                     | 35 (70.0)                                     |

Data are n (%) or mean ± s.e. or median (IQR). The analysis was based on the modified full-analysis cohort, with some participants reclassified into the correct groups according to the vaccines that they actually received. *Seropositivity for neutralizing antibody against SARS-CoV-2 before receiving a booster vaccination at day 0 is defined as a detectable neutralizing antibody titer ≥1:4.

Preliminary safety data. Within 28 d after boosting, a significantly higher frequency of adverse reactions reported by participants in group A was observed than in participants in group B (34.4% versus 4.9%, P < 0.0001) (Table 2). Similarly, a significantly higher frequency of adverse reactions was reported in group C than in group D (25.3% versus 8.0%, P = 0.0188). Participants in group A reported more solicited injection site events (for definition, see Assessments; 29.2% versus 2.9%, P < 0.0001) and systemic reactions (14.6% versus 2.9%, P = 0.0035) than those in group B. Participants in group C also reported a higher occurrence of solicited injection site reactions than those in group D (P = 0.0012). All adverse reactions were generally mild or moderate in severity, and typically resolved within 1 or 2 d. The only severe reaction was pain at the injection site, which was reported in 2.1% of Convidecia recipients but not in any CoronaVac recipient. The use of antipyretic agents was more frequent among Convidecia recipients (seven of 147, 4.8%) than among those who received CoronaVac (one of 152, 0.7%) (P = 0.0340), although absolute rates remained low. Incidence of unsolicited adverse events within 28 d after vaccination were low across the treatment groups (Extended Data Table 1). No thromboses, vaccine-related anaphylaxis or other serious adverse events were observed in any of the groups by day 28 after the booster. These data indicate that heterologous boosting with Convidecia following one or two doses of CoronaVac has a good and manageable safety profile, despite the higher reactogenicity than that resulting from homologous boosting with CoronaVac.

Neutralizing antibody responses against wild-type virus. Significant increases in neutralizing antibody levels against wild-type SARS-CoV-2 were observed after booster dose vaccination in all groups (Fig. 2). Post-vaccination GMTs of heterogeneous groups (groups A and C) were not only not inferior but also superior to those of homologous groups (groups B and D) in both the three-dose and two-dose regimen cohorts (Extended Data Table 2). GMTs of neutralizing antibodies against wild-type SARS-CoV-2 at day 0 before vaccination were 2.5 (95% confidence interval (CI) = 2.3, 2.7) and 2.2 (95% CI = 2.1, 2.3) in groups A and B, respectively. These titers increased to 197.4 in group A (95% CI = 167.7, 232.4) and 33.6 in group B (95% CI = 28.3, 39.8) at day 14 after the booster (P < 0.0001 for superiority). At baseline, neutralizing antibody GMTs of 2.1 (95% CI = 2.0, 2.3) and 2.1 (95% CI = 2.0, 2.1) were noted in groups C and D, respectively. These GMTs increased to 54.4 in group C (95% CI = 37.9, 78.0) and 12.8 in group D (95% CI = 9.3, 17.5) at day 14 after the booster (P < 0.0001 for superiority). In the three-dose regimen groups, the heterologous booster led to a geometric mean fold increase (GMFI) of 78.3 in neutralizing antibody levels against wild-type SARS-CoV-2, while the homologous booster with CoronaVac led to a GMFI of 15.2 (group A versus group B, P < 0.0001). In the two-dose regimen groups, GMTs of neutralizing antibodies against wild-type SARS-CoV-2 in participants receiving the heterologous booster increased 25.7-fold, and they increased by 6.2-fold in participants receiving a homologous booster with CoronaVac (group C versus group D, P < 0.0001). At day 28 after the booster, neutralizing antibody GMTs decreased slightly in all groups. However, neutralizing antibody GMTs against wild-type SARS-CoV-2 in group A (150.3; 95% CI = 128.6, 175.7) and group C (49.6; 95% CI = 35.1, 70.2) were still significantly higher than those in group B (35.3; 95% CI = 29.4, 42.4) and group D (10.6; 95% CI = 8.3, 13.5), respectively. Lower levels of neutralizing antibodies were found in group B recipients over 51 years of age than levels in those between 18 and 50 years of age (P < 0.0001; Extended Data Fig. 1), but no significant differences in vaccine-induced neutralizing antibody levels were found between age subgroups or between sexes in groups A, C and D. A post hoc analysis showed that higher levels of baseline anti-AD5 neutralizing antibodies were associated with statistically significant lower levels of neutralizing antibodies against SARS-CoV-2 in group A, but the levels were only numerically lower in group C (P = 0.0027 and 0.5921, respectively;
Extended Data Table 3). Our data suggest that heterologous boosting with Convidecia is more immunogenic than homologous boosting with CoronaVac.

**RBD-specific and N-specific antibodies.** In line with the neutralizing antibody titers, both heterologous and homologous boosters induced significant increases in RBD-binding IgG levels at day 14 (Fig. 3). However, heterologous boosting elicited significantly higher RBD-binding IgG GMTs than homologous boosting in both group A (3,090.1; 95% CI = 2,636.1, 3,622.3) versus group C (941.8; 95% CI = 663.9, 1,336.1) and group B (369.0; 95% CI = 304.2, 447.5) versus group D (154.1; 95% CI = 116.3, 204.3), with \( P < 0.0001 \).

Anti-RBD IgG antibody responses were predominantly associated with IgG1 levels after the booster in all heterologous or homologous vaccine groups (Extended Data Fig. 2). Increased IgG3 levels were found in participants receiving Convidecia (groups A and C) but not in those receiving CoronaVac (groups B and D). Low levels of IgG2 or IgG4 after the booster were observed across the treatment groups. At day 14, the mean IgG1/IgG4 ratios were 42.4 (95% CI = 35.6, 50.6) and 6.1 (95% CI = 5.2, 7.1) for group A and group B. The mean IgG1/IgG4 ratios were 24.4 (95% CI = 17.7, 33.6) and 3.8 (95% CI = 3.1, 4.6) for group C and group D at the same point. Participants in all groups had similar levels of N-specific binding antibodies at baseline, but only participants who received CoronaVac exhibited increases in both RBD-specific IgG and N-specific IgG levels (Fig. 3). There was no increase in N-specific IgG levels in Convidecia recipients after the booster. RBD-binding antibody levels positively correlated with neutralizing antibody titers in all groups, with correlation coefficients ranging from 0.61 to 0.8 (Extended Data Fig. 3). We conclude that heterologous boosting with Convidecia elicited significantly higher RBD-specific IgG levels (but not N-specific IgG levels) than did homologous boosting with CoronaVac.

Neutralizing antibody responses against the Delta variant. Neutralizing antibody GMTs against the SARS-CoV-2 Delta variant were significantly increased at day 14 after the booster in all groups (Fig. 2). Participants in group A had GMTs of neutralizing antibodies against the Delta variant of 55.0 (95% CI = 44.5, 68.0) compared with a GMT of 8.2 (95% CI = 6.6, 10.1) in group B (\( P < 0.0001 \)). GMTs of neutralizing antibodies against the Delta variant at day 14 in group C and group D were 10.8 (95% CI = 7.1, 16.5) and 3.6 (95% CI = 2.9, 4.4), respectively (\( P < 0.0001 \)). Compared with GMTs of neutralizing antibodies against the wild-type isolate, levels of neutralizing antibodies for the Delta variant were around 3.6–5.0-fold lower across the treatment groups. Nevertheless, heterologous

**Table 2 | Solicited and unsolicited adverse reactions that occurred within 28 d after vaccination**

| Solicited adverse reactions within 28 d | Group A (two doses primed + Convidecia, \( n = 96 \)) | Group B (two doses primed + CoronaVac, \( n = 102 \)) | \( P \) value | Group C (one dose primed + Convidecia, \( n = 51 \)) | Group D (one dose primed + CoronaVac, \( n = 50 \)) | \( P \) value |
|---|---|---|---|---|---|---|
| Any | 33 (34.4) | 5 (4.9) | \(<0.0001\) | 13 (25.5) | 4 (8.0) | 0.0188 |
| Severe | 2 (2.1) | 0 (0.0) | 0.2338 | 0 (0.0) | 0 (0.0) | – |

**Injection site adverse reactions**

| Total | Any | 28 (29.2) | 3 (2.9) | \(<0.0001\) | 12 (23.5) | 1 (2.0) | 0.0012 |
| Severe | 2 (2.1) | 0 (0.0) | 0.2338 | 0 (0.0) | 0 (0.0) | – |
| Pain | Any | 25 (26.0) | 3 (2.9) | \(<0.0001\) | 10 (19.6) | 1 (2.0) | 0.0045 |
| Severe | 2 (2.1) | 0 (0.0) | 0.2338 | 0 (0.0) | 0 (0.0) | – |

**Induration**

| Any | 9 (9.4) | 0 (0.0) | 0.0012 | 4 (7.8) | 0 (0.0) | 0.1176 |

**Redness**

| Any | 12 (12.5) | 0 (0.0) | 0.0002 | 5 (9.8) | 0 (0.0) | 0.0564 |

**Swelling**

| Any | 9 (9.4) | 0 (0.0) | 0.0012 | 5 (9.8) | 0 (0.0) | 0.0564 |

**Itch**

| Any | 10 (10.4) | 0 (0.0) | 0.0025 | 5 (9.8) | 0 (0.0) | 0.0564 |

**Systemic adverse reactions**

| Total | Any | 14 (14.6) | 3 (2.9) | 0.0035 | 6 (11.8) | 3 (6.0) | 0.4874 |
| Fever | Any | 4 (4.2) | 0 (0.0) | 0.0535 | 3 (5.9) | 1 (2.0) | 0.6175 |
| Headache | Any | 2 (2.1) | 0 (0.0) | 0.2338 | 1 (2.0) | 0 (0.0) | >0.9999 |
| Fatigue | Any | 11 (11.5) | 3 (2.9) | 0.0195 | 4 (7.8) | 2 (4.0) | 0.6779 |
| Diarrhea | Any | 0 (0.0) | 1 (1.0) | \( >0.9999 \) | 0 (0.0) | 0 (0.0) | – |
| Muscle pain | Any | 1 (1.0) | 0 (0.0) | 0.4848 | 1 (2.0) | 0 (0.0) | >0.9999 |
| Joint pain | Any | 1 (1.0) | 1 (1.0) | \( >0.9999 \) | 0 (0.0) | 0 (0.0) | – |
| Throat pain | Any | 1 (1.0) | 1 (1.0) | \( >0.9999 \) | 0 (0.0) | 0 (0.0) | – |
| Cough | Any | 0 (0.0) | 0 (0.0) | – | 1 (2.0) | 0 (0.0) | >0.9999 |
| Nausea | Any | 0 (0.0) | 0 (0.0) | – | 1 (2.0) | 0 (0.0) | >0.9999 |

**Unsolicited adverse reactions within 28 d**

| Total | Any | 1 (1.0) | 0 (0.0) | 0.4848 | 0 (0.0) | 0 (0.0) | – |
| Dizziness | Any | 1 (1.0) | 0 (0.0) | 0.4848 | 0 (0.0) | 0 (0.0) | – |
| Muscle pain | Any | 1 (1.0) | 0 (0.0) | 0.4848 | 0 (0.0) | 0 (0.0) | – |

Data are \( n \) (%), \( n \) number of participants; %, proportion of participants; any, all participants with any grade of adverse reactions or event. The analysis was based on the intervention modified intention-to-treat cohort. \( P \) values shown in bold are <0.05.
Fig. 2 | Neutralizing antibodies to wild-type SARS-CoV-2 or the Delta variant before and after boosting. GMTs of neutralizing antibodies to wild-type SARS-CoV-2 (a) or the Delta variant B.1.617.2 (b). GMFI of neutralizing antibodies to wild-type SARS-CoV-2 (c) or the Delta variant B.1.617.2 (d). Seroconversion of neutralizing antibodies to wild-type SARS-CoV-2 (e) or the Delta variant B.1.617.2 (f). Error bars indicate 95% CIs. n, the number of participants included the intervention modified intention-to-treat cohort; seroconversion, proportion of participants with at least a fourfold increase in post-vaccination antibody levels compared to levels before the booster vaccination. Group A, primed with two doses of CoronaVac and given one dose of Convidecia (n=96); group B, primed with two doses of CoronaVac and given one dose of CoronaVac (n=102); group C, primed with one dose of CoronaVac and given one dose of Convidecia (n=51); group D, primed with one dose of CoronaVac and given one dose of CoronaVac (n=50). The analysis was based on the intervention modified intention-to-treat cohort. Measurements on day 0 were taken immediately before vaccination. The WHO reference (1,000 IU ml\(^{-1}\) in serum) is equivalent to a live viral neutralizing antibody titer of 1:320 against wild-type SARS-CoV-2 and 1:80 against the Delta variant B.1.617.2. P values result from comparison between the two treatment groups using t-tests for log-transformed antibody titers or two-sided \(\chi^2\) tests for categorical data (group A versus group B and group C versus group D). No adjustments were made for multiple comparisons (group A versus group B and group C versus group D). For (e,f), the statistics are proportions of participants with seroconversion after the vaccination. **\(P<0.005\), ****\(P<0.0001\).
Vaccination with Convidecia induced significantly higher neutralizing antibody levels against the Delta variant than homologous immunization with CoronaVac (Fig. 2).

**Vaccine-induced T cell responses.** An enzyme-linked immunospot (ELISpot) assay was used to quantify virus-specific T cell responses by measuring the secretion of interferon (IFN)-γ, tumor necrosis factor (TNF)-α, interleukin (IL)-4, IL-5 and IL-13 after stimulating peripheral blood mononuclear cells (PBMCs) with peptides (Methods)\(^1\). We observed an increase in the levels of IFN-γ, which is produced by type 1 helper T (T_H1) cells (among other immune cells), across all treatment groups at 14 d after the booster (Fig. 4a). Participants in group A had median IFN-γ+ spot counts of 65 per 10^6 PBMCs (interquartile range (IQR) = 40, 135) compared with a count of 60 per 10^6 PBMCs (IQR = 20, 170) in group B. Lower IFN-γ+ spot counts were observed in group C (45 per 10^6 PBMCs; IQR = 30, 75) and group D (30 per 10^6 PBMCs; IQR = 10, 40). Baseline levels of TNF-α were comparably high across all groups and only increased slightly after the booster (Fig. 4b). Higher post-vaccination IL-4, IL-5 and IL-13 ELISpot counts were noted in the groups receiving homologous CoronaVac vaccination, suggesting type 2 helper T (T_H2) cell skewing in these recipients (Fig. 4c–e). Overall, we observed a cytokine profile that might be suggestive of TH1 skewing in both heterologous booster
In our study, the heterologous prime-boost regimen with one dose of Convidecia administered at an interval of 3–6 months after two doses of CoronaVac was safe and highly immunogenic in healthy adults aged 18–59 years. The neutralizing antibody GMT at day 14 after the heterologous booster was 197.4 in group A, which is equivalent to 616.9 IU ml\(^{-1}\) (95% CI = 524.1, 726.3 IU ml\(^{-1}\)) using the World Health Organization (WHO) international standard (Methods)\(^1\). This is comparable to 676.1 IU ml\(^{-1}\) (95% CI = 517.5, 883.3 IU ml\(^{-1}\)) in participants primed with Janssen Ad26.COV2-S and then given a booster of Moderna mRNA-1273 and to 677.9 IU ml\(^{-1}\) (95% CI = 559.4, 821.3 IU ml\(^{-1}\)) in participants primed with Moderna mRNA-1273 and then given a booster of Pfizer BNT162b2, as reported in a previous heterologous booster study\(^2\). Heterologous immunization in group A elicited 5.9-fold (GMT, 197.4 versus 33.6) and 6.8-fold (GMT, 53.8 versus 7.9) higher levels of neutralizing antibodies to wild-type SARS-CoV-2 and the Delta variant than did groups A and C compared to the homologous booster groups B and D (Fig. 4f).

**Discussion**

In our study, the heterologous prime-boost regimen with one dose of Convidecia administered at an interval of 3–6 months after two doses of CoronaVac was safe and highly immunogenic in healthy adults aged 18–59 years. The neutralizing antibody GMT at day 14 after the heterologous booster was 197.4 in group A, which is equivalent to 616.9 IU ml\(^{-1}\) (95% CI = 524.1, 726.3 IU ml\(^{-1}\)) using the World Health Organization (WHO) international standard (Methods)\(^1\). This is comparable to 676.1 IU ml\(^{-1}\) (95% CI = 517.5, 883.3 IU ml\(^{-1}\)) in participants primed with Janssen Ad26.COV2-S and then given a booster of Moderna mRNA-1273 and to 677.9 IU ml\(^{-1}\) (95% CI = 559.4, 821.3 IU ml\(^{-1}\)) in participants primed with Moderna mRNA-1273 and then given a booster of Pfizer BNT162b2, as reported in a previous heterologous booster study\(^2\). Heterologous immunization in group A elicited 5.9-fold (GMT, 197.4 versus 33.6) and 6.8-fold (GMT, 53.8 versus 7.9) higher levels of neutralizing antibodies to wild-type SARS-CoV-2 and the Delta variant than did
homologous immunization in group B. Based on these data, a heterologous prime–boost vaccination with Convidecia after priming with CoronaVac could potentially offer additional protection against SARS-CoV-2 as compared to a third dose of CoronaVac. However, levels of baseline neutralizing antibodies against SARS-CoV-2 were slightly higher in group A than those in group B, which may have biased neutralizing antibody levels after the booster dose.

The improved immunogenicity outcomes associated with heterologous boosting with Convidecia may result from memory responses targeted to the spike protein, rather than the whole virus, which mainly contains non-neutralizing viral epitopes. Heterologous boosting could also elicit strong T cell responses, which improve the breadth of immunity and overcome the limitations of the individual vaccine platforms24–26. Relatively higher T cell-secreted IL-4 levels were noted in individuals after the booster, especially in individuals receiving a homologous CoronaVac booster as a third dose, which was not reported in a previous CoronaVac trial. Th2 cytokines such as IL-4, IL-5 and IL-13 are generally regarded as important drivers of immunopathology. We note that we did not measure levels of any cytokines, including IL-4, in plasma or bronchoalveolar lavage samples. The increase in IL-4 levels may need to be further investigated in populations initially primed with inactivated vaccines after the third dose.

Participants who received the heterologous three-dose regimen (group A) had the highest levels of neutralizing antibodies against SARS-CoV-2 at day 14 after the booster, followed by those who received the heterologous two-dose regimen (group C) and then those who received the homologous three-dose regimen (group B) and those who received the homologous two-dose regimen (group D). Although the 28-d homologous two-dose inactivated vaccine regimen was the least immunogenic of the four regimens in our study, this is a licensed vaccine schedule that has met the minimum efficacy (50%) defined by the WHO, reducing hospitalization and death by over 86% in both phase 3 trials and post-license studies5,27–29.

A longer interval between the prime and the booster is usually associated with higher levels of neutralizing antibodies, as the affinity maturation of memory B cells induced by vaccination could take months30–32. However, the waning of virus-specific antibodies and low levels of neutralizing antibodies against SARS-CoV-2 in vaccinated individuals at 3 months after the two-dose CoronaVac regimen are potentially worrisome. Based on our data, we would recommend the administration of a single dose of Convidecia to individuals who have completed the primary series of the two-dose CoronaVac regimen 3 months ago.

Our study provides evidence supporting the safety and immunogenicity of a heterologous COVID-19 vaccine regimen with an inactivated vaccine and an AD5 vector-based vaccine. To date, at least four studies evaluating heterologous prime–boost regimens have been reported. rAd26 and rAd5 vector-based heterologous prime–boost COVID-19 vaccine regimens induced a robust immune response and had 91.6% efficacy against symptomatic disease33,34. Two heterologous prime–boost vaccination studies with ChAdOx1 nCoV-19 and BNT162b2 elicited higher IgG concentrations than that of a licensed homologous schedule (ChAd/ChAd)24,25. Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and mRNA-1273 led to an increase in titers of serum neutralizing antibodies against the wild-type and the B.1.351 variant of SARS-CoV-2, in contrast to a homologous ChAdOx1 nCoV-19 booster26. One of these studies reported higher reactogenicity with the heterologous prime–boost vaccination regimen27. Evidence from these studies and results of this trial suggest that heterologous prime–boost regimens are more immunogenic than homologous prime–boost regimens, but they may in some instances be more reactogenic.

There are several limitations to this study. First, only adults between 18 and 59 years of age were enrolled and not older adults who are often immunocompromised or have coexisting conditions and respond more poorly to vaccines. We are conducting another trial to evaluate heterologous prime–boost vaccination with CoronaVac and Convidecia in an older population (NCT04952727). Second, we did not perform a power calculation before initiating the trial for evaluating heterologous versus homologous vaccination following one dose of inactivated vaccine (groups C and D), and this may have resulted in an underpowered comparison between groups C and D. Third, studies on the mechanisms underpinning enhanced immune responses following heterologous prime–boost regimens were not performed; therefore, we can only speculate about the reasons why these regimens were more immunogenic. Fourth, we did not assess the efficacy of the heterologous prime–boost vaccination regimen against symptomatic or severe COVID-19, and the protection associated with this heterologous regimen remains undefined. However, a previous study found that neutralization activity against SARS-CoV-2 is highly predictive of vaccine protection35, which suggests that heterologous prime–boost vaccination with Convidecia after CoronaVac would likely be more protective than homologous vaccination with CoronaVac. Finally, the relatively small number of participants in this study could result in some uncertainty or bias, particularly given the difference in neutralizing antibody levels at enrollment between treatment groups A and B for the three-dose regimens. The small sample sizes were insufficient to identify potentially increased risks for some rare but severe adverse reactions, such as vaccine-induced immune thrombotic thrombocytopenia. In addition, due to the short follow-up period in this report, the long-term safety profile and durability of the immune response following the booster are unclear. Follow-up until 6 months after the booster for the safety and immunogenicity of these regimens is ongoing.

In conclusion, the heterologous prime–boost regimens with the inactivated vaccine CoronaVac and the AD5-vectored vaccine Convidecia were safe and highly immunogenic. The strong enhancement of antibody titers after heterologous boosting is encouraging, but the durability of these antibodies still needs further investigation, along with the neutralizing activity of these antibodies against other variants of concern, such as the recently emerged Omicron variant (B.1.1.529). Our results support flexibility in the use of Convidecia and CoronaVac vaccines, which might accelerate vaccine rollout in some settings.

**Online content**

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at [https://doi.org/10.1038/s41591-021-01677-z](https://doi.org/10.1038/s41591-021-01677-z).

Received: 17 October 2021; Accepted: 22 December 2021; Published online: 27 January 2022

**References**

1. Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. The Lancet Infect. Dis. 20, 533–534 (2020).
2. Palacios, R. et al. Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV Study. SSRN [https://doi.org/10.2139/ssrn.3822780 (2021)].
3. Halperin, S. A. et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet 399, 237–248 (2022).
4. Xinhua. Over 1.8 bln doses of COVID-19 vaccines administered in China. Xinhua. [http://www.xinhuanet.com/english/2021-08/11/c_1310121275.htm (4 August 2021)].
5. VIPER Group COVID19 Vaccine Tracker Team. COVID19 Vaccine Tracker. [https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/] (2021).
6. Lim, W. W., Mak, L., Leung, G. M., Cowling, B. J. & Peiris, M. Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19. *Lancet Microbe* **2**, e423 (2021).

7. Zeng, G. et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. *Lancet Infect. Dis.* [https://doi.org/10.1016/s1473-3099(21)00681-2](https://doi.org/10.1016/s1473-3099(21)00681-2) (2021).

8. Zhu, F. et al. Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine with a homologous prime–boost regimen in healthy participants aged 6 years and above: a randomised, double-blind, placebo-controlled, phase 2b trial. *Clin. Infect. Dis.* [https://doi.org/10.1093/cid/ciaa845](https://doi.org/10.1093/cid/ciaa845) (2021).

9. Xu, J. L. & Kim, J. H. Novel prime–boost vaccine strategies against HIV-1. *Expert Rev. Vaccines* **18**, 765–779 (2019).

10. He, Q. et al. Heterologous prime–boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. *Emerg. Microbes Infect.* **10**, 629–637 (2021).

11. Zhu, F. C. et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet* **396**, 479–488 (2020).

12. Kristiansen, P. A. et al. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. *Lancet* **397**, 1347–1348 (2021).

13. Atmar, R. L. et al. Heterologous SARS-CoV-2 booster vaccinations—preliminary report. Preprint at medRxiv [https://doi.org/10.1101/2021.10.21.21258427](https://doi.org/10.1101/2021.10.21.21258427) (2021).

14. Lu, S. Heterologous prime–boost vaccination. *Curr. Opin. Immunol.* **21**, 346–351 (2009).

15. Kardani, K., Bolhassani, A. & Shahbazi, S. Prime–boost vaccine strategy against viral infections: mechanisms and benefits. *Vaccine* **34**, 413–423 (2016).

16. Ramshaw, I. A. & Ramsay, A. J. The prime–boost strategy: exciting prospects for improved vaccination. *Immunol. Today* **21**, 163–165 (2000).

17. Victora, P. C. et al. Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: analyses of routinely-collected data on vaccine coverage and mortality. *EClinicalMedicine* **38**, 101036 (2021).

18. Tannriover, M. D. et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. *Lancet* **398**, 213–222 (2021).

19. Jara, A. et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. *N. Engl. J. Med.* **385**, 875–884 (2021).

20. Juno, J. A. & Wheatley, A. K. Boosting immunity to COVID-19 vaccines. *Nat. Med.* **27**, 1874–1875 (2021).

21. Sallusto, F., Lanzavecchia, A., Araki, K. & Ahmed, R. From vaccines to memory and back. *Immunity* **3**, 451–463 (2010).

22. Logunov, D. Y. et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime–boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. *Lancet* **396**, 887–897 (2020).

23. Logunov, D. Y. et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime–boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. *Lancet* **397**, 671–681 (2021).

24. Liu, X. et al. Safety and immunogenicity of heterologous versus homologous prime–boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV); a single-blind, randomised, non-inferiority trial. *Lancet* **398**, 856–869 (2021).

25. Hillus, D. et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime–boost immunisation with ChAdOx1-nCoV19 and BNT162b2: a prospective cohort study. Preprint at medRxiv [https://doi.org/10.1101/2021.05.19.21257334](https://doi.org/10.1101/2021.05.19.21257334) (2021).

26. Normark, J. et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination. *N. Engl. J. Med.* **385**, 1049–1051 (2021).

27. Shaw, R. H. et al. Heterologous prime–boost COVID-19 vaccination: initial reactogenicity data. *Lancet* **397**, 2043–2046 (2021).

28. Lustig, Y. et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. *Lancet Respir. Med.* **9**, 999–1009 (2021).
Methods
Study design. We conducted a single-center, randomized, controlled, observer-blinded trial to access the safety and immunogenicity of heterologous prime–boost immunization with CoronaVac and Convidecia. The trial was reviewed and approved by the Research Ethics Committee of the Jiangsu Provincial Center of Disease Control and Prevention, and no changes to the protocol were made after the initiation of the study. Written informed consent was obtained from each participant before inclusion. No data- and safety-monitoring board was set up for this study. This trial was prospectively registered with https://clinicaltrials.gov/ (NCT049824159) and conducted following the principles of the Declaration of Helsinki, ICH Good Clinical Practice guidelines and local guidelines.

Participants. Community doctors recruited participants from one clinic site in Lianshui County, Jiangsu Province. Healthy participants, male or female, between 18 and 59 years of age, who had completed one-dose priming of CoronaVac in the past 1–3 months or two-dose priming of CoronaVac in the past 3–6 months, were recruited for eligibility screening. Investigators verified the vaccination record and checked the medical history of each participant. Participants with a previous clinical or virologic COVID-19 diagnosis or SARS-CoV-2 infection or women with positive urine pregnancy test results were excluded from this study. Participants with a medical history of convulsion, serious acute hyperpyrexial reaction to vaccines, acute febrile diseases or infectious diseases, congenital or acquired angioedema, asplenia or functional asplenia, thrombocytopenia or other coagulation disorders, needle sickness, any serious chronic conditions or utricaria within 1 year and those receiving anti-tuberculosis treatment, immunosuppressive therapy, anti-allergy therapy, cytotaxic therapy in the past 6 months or blood products within 4 months were also excluded.

Randomization. We used an interactive web-based response-randomization system stratified according to the number of priming doses that the participants had received. Eligible participants who had completed the two-dose schedule of CoronaVac in the past 3–6 months were randomly assigned at a 1:1 ratio to receive a booster dose of Convidecia (group A, heterologous booster dose) or CoronaVac (group B, homologous booster dose), while participants who had been primed with one dose of CoronaVac in the past 1–3 months were randomized at a 1:1 ratio to receive a second dose of Convidecia (group C, heterologous dose) or CoronaVac (group D, homologous dose). Randomization lists were generated by an independent statistician using SAS (version 9.4).

We masked investigators, laboratory staff and outcome assessors to the allocation of treatment groups but not to the three-dose or two-dose regimen. As the vials and syringes for Convidecia and CoronaVac were different, designated unblinded personnel were responsible for vaccine preparation and administration. The original labels on the syringes for injection were concealed with a label for the randomization number before use. The unblinded personnel did not participate in any other process of the trial and were forbidden to reveal the identity of the study vaccines to any other investigators.

Interventions. One of the study vaccines, CoronaVac (Sinovac), is an inactivated whole-virion vaccine with aluminum hydroxide as the adjuvant and was developed in China. Each dose of COVID-19 vaccine contains 3 μg SARS-CoV-2 virion in a 0.5-ml aqueous suspension for injection with 0.45 mg mL⁻¹ aluminum. The other study vaccine is Convidecia (CanSino), a recombinant AD5-vectorized COVID-19 vaccine, which contains 5 x 10¹⁰ viral particles per dose.

Assessments. After the booster vaccination, all participants were observed at the clinic for 30 min after vaccination for any immediate vaccine-associated reactions and then were instructed to keep a daily record of any solicited or unsolicited adverse events for the next 14 d on a participant diary card. Solicited injection site reactions were severe localized pain, redness, swelling, induration, itch and cellulitis, while systemic events included fever, malaise, muscle ache, joint pain, fatigue, nausea, headache and so on. Unsolicited adverse events within 28 d and reported by the participants were also collected. Adverse events were graded for severity according to the standard guidelines issued by the China State Food and Drug Administration and the causality with immunization before unmasking. Serious adverse events that were self-reported by participants were documented throughout the study. A 20-ml blood sample was collected from each participant at baseline before they received the booster dose and at 14 and 28 d after receiving the booster dose.

Endpoints. The primary endpoint for the safety objective was the occurrence of adverse reactions within 28 d after vaccination. The primary endpoint for immunogenicity was the GMTs of neutralizing antibodies against live SARS-CoV-2 virus at 14 d after booster vaccination. Live viral neutralizing antibody titers against the wild-type strain and the Delta variant B.1.617.2 in serum were determined by using a cytopathic effect-based microneutralization assay with the wild-type SARS-CoV-2 viral isolate BetaCoV/Jiangsu/S02/2020 (GISAID EPI_ISL_411952) and a Delta variant, hCoV-19/China/S07/2021 (GISAID EPI_ISL_451846), in Vero E6 cells (National Collection of Authenticated Cell Cultures, National Academy of Science, China). Serum dilutions were then mixed with the same volume of viral solution to achieve a final concentration of 100 TCID₅₀ per well. The reported titrer was the reciprocal of the highest sample dilution that protected at least 50% of cells from cytopathic effects. Serum dilution for the microneutralization assay started from 1:4, and serum dilution for the titration procedure was defined as 1:4.

RBD- and N-specific ELISA antibody responses were measured at the same time points, using an indirect ELISA assay with a cutoff titer of 1:10. The commercial Anti-SARS-CoV-2 RBD IgG ELISA kit (Vazyme Medical Technology) was used for detection. RBD-specific and N-specific binding antibodies were detected using a horseshadish peroxidase-conjugated secondary antibody (ABC20021003516, Vazyme Medical Technology) diluted for each ELISA assay (anti-RBD antibody detection, 1:18,000; anti-N antibody detection, 1:15,000) and TMB substrate (Surmodica). Data collection was performed using a Multiskan GO reader (Thermo Fisher) to detect optical density at 450 and 630 nm using SkanIt Software for Microplate Readers (version 4.1.0.43). We validated the RBD-specific and N-specific measuring approaches by detecting SARS-CoV-2 RBD antibodies and the titers of spike protein-specific antibodies using sera isolated from participants at 14 d after the booster dose. We observed a high correlation between the two approaches, with r = 0.91 (Supplementary Fig. 1), and then proceeded with the RBD-specific antibody-measuring system.

The WHO international standard for anti-SARS-CoV-2 IgG (NIBSC code 20/136) was used side by side as reference with the serum samples measured in this study for calibration and harmonization of the serological assays. The WHO reference (NIBSC code: 20/136) is equivalent to a live viral neutralizing antibody titer of 1:320 against wild-type SARS-CoV-2 and a titer of 1:80 against the WHO reference (B.1.617.2, which is a WHO reference strain) is equivalent to an RBD-specific IgG ELISA antibody titer of 1:2,430. All serum samples from eligible participants were used for humoral immune measurements, including for the live viral neutralizing antibody against the wild-type isolate and for RBD- and N-specific ELISAs. Live viral neutralizing antibodies against the Delta variant B.1.617.2 were only detected at day 0 and 14 after the booster. RBD-specific binding in serum was measured at day 14, and the ratio of IgG1/IgG4 was used to evaluate Th1/Th2 profiling.

The AD5-neutralization assay was based on the firefly luciferase assay system. Heat-inactivated human serum samples were diluted in duplicate at an initial factor of 1:12, followed by a threefold dilution series. No serum was added to the positive control wells, in which maximum luciferase activity was assumed to represent 90% neutralization values. Ad5-Luciferase was mixed with an equal volume of each diluted serum sample and incubated for 1 h in a 96-well plate. Next, a suspension of A549 cells (American Strain Preservation Center) was added to the mixture. After 24 h of culture at 37 °C, cells were washed and lysed. Luciferase activity was determined using the Firefly Luciferase Assay system (Promega), and values were determined using the GloMax Microplate luminometer (Promega).

PBMCs from blood samples of the first 50 and 30 participants in the three-dose and two-dose regimen cohorts before and at 14 d after the booster were used to evaluate cellular immunity. PBMCs were isolated by Ficoll-Paque PLUS (Cytiva) density gradient centrifugation and cryopreserved before analysis. Peptide pools covering the full-length spike glycoprotein were prepared at a concentration of 2 μg per well, and 100,000 cells per well were added to the plate. PBMCs were stimulated with the peptide pools, and T₄₁-secreted cytokines (IFN-γ and TNF-α) and T₂-secreted cytokines (IL-4, IL-5 and IL-13) were detected by the ELISPOT assay (Mabtech) Plates were printed, and spots were counted on the Cellular Tracking ImmunoSpot Analyzer. The ELISPOT assay is an enzyme-linked assay that is qualified for human serum at the laboratory of Vazyme Biotech. Each data point represents the normalized mean spot count from duplicate wells for one study participant after subtraction of the value of the unstimulated control.

Sample size. Sample size calculation was based on the hypothesis that a heterogeneous booster vaccination following the two-dose inactivated vaccine regimen would elicit a non-inferior or superior level of neutralizing antibody to the homologous booster vaccination (groups A and B) and was performed by using Power Analysis and Sample Size software (version 11.0.7). We assumed that the GMT of neutralizing antibodies was approximately 1:40 at baseline before receiving the booster immunization (that is, 3–6 months after receiving two doses of the inactivated vaccine). The probability was set to reach 1:80 for those receiving a homologous dose of CoronaVac and 1:160 for those receiving a heterologous dose of Convidecia at day 14. A standard deviation of 4 for GMTs was estimated for both groups. A sample size of 100 participants per treatment group would provide over 99% power to identify non-inferiority in log-transformed post-vaccination GMTs of neutralizing antibodies at a non-inferiority margin of 0.67 and at least 90% power for detecting at least 95% inferiority of heterologous treatment at a one-sided significance level of 0.025. The probability of observing a particular adverse event with an incidence of 2% at least once in 100 participants in each group was 86.7%. In addition, heterologous vaccination following one dose of inactivated vaccine (groups C and D) was also explored but was not considered in the power analysis due to the low probability of this event (the power was not precalculated, which may result in an underpowered comparison). However, a post hoc power calculation showed that the sample size of 50 individuals per group for the two-dose regimen cohort could provide power greater than 99% to show differences between heterologous and homologous groups.
Statistical analysis. We assessed the number and proportion of participants with adverse reactions after vaccination. Levels of antibodies against SARS-CoV-2 were presented as GMTs, GMFIs and the proportion of participants with at least a fourfold increase with 95% CIs. The GMT ratios of the heterogeneous group versus the homologous group were calculated, and non-inferiority was achieved when the lower limit of the 95% CI of the GMT ratio exceeded 0.67. We used the $\chi^2$ test or Fisher's exact test to analyze categorical data, the t-test to analyze the log-transformed antibody titers and the Wilcoxon rank-sum test for data not following a normal distribution. The correlation between concentrations of log-transformed neutralizing antibody and binding antibody levels was analyzed using Pearson's correlation. Calculating neutralizing antibodies against SARS-CoV-2 by stratifying levels of pre-existing anti-AD5 neutralizing antibody titers as low or negative ($\leq 1:200$) or high ($> 1:200$) by using pre-existing anti-AD5 neutralizing antibody titers. The primary analysis was performed based on the intervention modified intention-to-treat cohort, including all participants who were randomized and vaccinated. Statistical analyses were performed using SAS (version 9.4) or GraphPad Prism 8.0.1.

Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability
The study protocol and statistical analysis plan are available in the Supplementary Information. To protect participants' confidentiality, the individual participant data that underlie the results reported in this article (text, tables, figures and extended data) will only be shared after de-identification. Researchers who provide a scientifically sound proposal will be allowed to access to the de-identified individual participant data. Because this clinical trial is ongoing, data will be available for request 1 month after the completion of the study (anticipated in January 2022). Proposals should be directed to jszfc@vip.sina.com or cw0226@foxmail.com.

Code availability
All code used to produce the results can be accessed by sending a scientifically sound proposal to jszfc@vip.sina.com or cw0226@foxmail.com. Shared code will be made available with the associated raw data.

References
29. Nauta, J. Statistics in Clinical Vaccine Trials (Springer, 2011).

Acknowledgements
This work is funded by the National Natural Science Foundation of China (Jingxin L.) and the Jiangsu Provincial Key Research and Development Program (F.Z.). We acknowledge CanSino and Sinovac for providing the vaccines for this trial.

Author contributions
Jingxin L. is the principal investigator of this trial. F.Z., W.C., Jingxin L., L.H. and P.J. designed the trials and the study protocol. Jingxin L. drafted the manuscript. F.Z. and W.C. contributed to critical review and revising of the report. Jingxin L., L.H. and P.J. contributed to data interpretation and revising the manuscript. X.G. led laboratory analyses. S.W., L.C., Jingxian L., F.S., X.X. and Y.C. contributed to laboratory tests. Xuewen W. was responsible for statistical analysis. T.Z. and H.P. contributed to study supervision. J.Z. and Z.S. led and participated in site work, including recruitment, follow-up and data collection. L.J. contributed to the literature search. Xue W., J.W. and J.L. monitored the trial.

Competing interests
X.W., J.W., J.L. and T.Z. are employees of CanSino Biologics. All other authors declare no competing interests.

Additional information
Extended data is available for this paper at https://doi.org/10.1038/s41591-021-01677-z.
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41591-021-01677-z.
Correspondence and requests for materials should be addressed to Wei Chen or Fengcai Zhu.

Peer review information Nature Medicine thanks Daniel Altmann, Alicia Widge and Michael Grayling for their contribution to the peer review of this work. Saheli Sadanand was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.

Reprints and permissions information is available at www.nature.com/reprints.
Extended Data Fig. 1 | GMT of neutralizing antibodies to wild-type SARS-CoV-2 at day 14 after vaccination stratified by age-subgroups and sex groups. (a) GMTs of neutralizing antibodies to wild-type SARS-CoV-2 stratified by age-subgroups in Group A and Group B. (b) GMTs of neutralizing antibodies to wild-type SARS-CoV-2 stratified by age-subgroups in Group C and Group D. (c) GMTs of neutralizing antibodies to wild-type SARS-CoV-2 stratified by sex-subgroups in Group A and Group B. (d) GMTs of neutralizing antibodies to wild-type SARS-CoV-2 stratified by sex-subgroups in Group C and Group D. Data are GMT (95% CI). Error bars indicate 95% CIs. Group A: primed with two doses of CoronaVac + Convidecia (n = 96); Group B: primed with two doses of CoronaVac + CoronaVac (n = 102); Group C: primed with one dose of CoronaVac + Convidecia (n = 51); Group D: primed with one dose of CoronaVac + CoronaVac (n = 50). The p values are the results of comparison using T test for log-transferred antibody titers by age-subgroups and sex groups in each treatment group. Measurements were on day 0 were taken immediately before vaccination. GMT = geometric mean titer. GMFI = geometric mean fold increase. ***P value < 0.001; ****P value < 0.0001.
Extended Data Fig. 2 | Receptor binding domain (RBD)-binding IgG isotypes before and after receiving a heterogeneous or homologous boost vaccine.

(a) GMTs of anti-RBD IgG1 isotypes, (b) IgG2 isotypes, (c) IgG3 isotypes and (d) IgG4 isotypes. Data are GMT (95% CI). Error bars indicate 95% CIs. Group A: primed with two doses of CoronaVac + Convidecia (n = 96); Group B: primed with two doses of CoronaVac + CoronaVac (n = 102); Group C: primed with one dose of CoronaVac + Convidecia (n = 51); Group D: primed with one dose of CoronaVac + CoronaVac (n = 50). The p values are the results of comparison between the two treatment groups using T test for log-transferred antibody titers (Group A vs. Group B, and Group C vs. Group D). All the paired data of RBD-binding antibodies from participants are included in the analysis. The discrepancies between the numbers of data points presented in the figures and the numbers of participants in the groups are due to the overlapping of the dots. **P value < 0.01; ****P value < 0.0001.
Extended Data Fig. 3 | Correlations between live SARS-CoV-2 neutralizing antibodies against the wild-type strain and receptor binding domain (RBD) antibodies by vaccine regimens at day 14 and 28 post-vaccination. (a) Correlations between live SARS-CoV-2 neutralizing antibodies against the wild-type strain and receptor binding domain (RBD) antibodies by vaccine regimens at day 14 and day 28 (b) in Group A and Group B. (c) Correlations between live SARS-CoV-2 neutralizing antibodies against the wild-type strain and receptor binding domain (RBD) antibodies by vaccine regimens at day 14 and day 28 (d) in Group C and Group D. Data are GMT (95% CI), GMFI (95% CI), and seroconversion (95% CI). Group A: primed with two doses of CoronaVac + Convidecia (n = 96); Group B: primed with two doses of CoronaVac + CoronaVac (n = 102); Group C: primed with one dose of CoronaVac + Convidecia (n = 51); Group D: primed with one dose of CoronaVac + CoronaVac (n = 50). Pearson correlation coefficients (95% CIs) are presented for each vaccine schedule. All the paired data of neutralizing antibodies and RBD-binding antibodies from participants are included in the analysis. The discrepancies between the numbers of data points presented in the figures and the numbers of participants in the groups are due to the overlapping of the dots.
### Extended Data Table 1 | Solicited and unsolicited adverse events occurred within 28 days after the vaccination

|                  | Group A (n=96) | Group B (n=102) | P value | Group C (n=51) | Group D (n=50) | P value |
|------------------|----------------|-----------------|---------|----------------|----------------|---------|
| **Solicited adverse events within 28 days** |                 |                 |         |                |                |         |
| Any              | 33 (34.4)      | 5 (4.9)         | <0.0001 | 13 (25.5)      | 4 (8.0)        | 0.0188  |
| Severe           | 2 (2.1)        | 0 (0.0)         | 0.2338  | 0 (0.0)        | 0 (0.0)        | -       |
| **Injection-site adverse events** |                 |                 |         |                |                |         |
| Total            | 28 (29.2)      | 3 (2.9)         | <0.0001 | 12 (23.5)      | 1 (2.0)        | 0.0012  |
| Severe           | 2 (2.1)        | 0 (0.0)         | 0.2338  | 0 (0.0)        | 0 (0.0)        | -       |
| Pain             | 25 (26.0)      | 3 (2.9)         | <0.0001 | 10 (19.6)      | 1 (2.0)        | 0.0046  |
| Severe           | 2 (2.1)        | 0 (0.0)         | 0.2338  | 0 (0.0)        | 0 (0.0)        | -       |
| **Systemic adverse events** |                 |                 |         |                |                |         |
| Total            | 14 (14.6)      | 3 (2.9)         | 0.0035  | 6 (11.8)       | 4 (8.0)        | 0.7400  |
| Fever            | 4 (4.2)        | 0 (0.0)         | 0.0535  | 3 (5.9)        | 1 (2.0)        | 0.6175  |
| Headache         | 2 (2.1)        | 0 (0.0)         | 0.2338  | 1 (2.0)        | 1 (2.0)        | >0.9999 |
| Fatigue          | 11 (11.5)      | 3 (2.9)         | 0.0195  | 4 (7.8)        | 2 (4.0)        | 0.6770  |
| Diarrhea         | 0 (0.0)        | 1 (1.0)         | >0.9999 | 0 (0.0)        | 0 (0.0)        | -       |
| Muscle pain      | 1 (1.0)        | 0 (0.0)         | 0.4848  | 1 (2.0)        | 0 (0.0)        | >0.9999 |
| Joint pain       | 1 (1.0)        | 1 (1.0)         | >0.9999 | 0 (0.0)        | 0 (0.0)        | -       |
| Throat pain      | 1 (1.0)        | 1 (1.0)         | >0.9999 | 0 (0.0)        | 1 (2.0)        | 0.4951  |
| Cough            | 0 (0.0)        | 0 (0.0)         | -       | 1 (2.0)        | 1 (2.0)        | >0.9999 |
| Nausea           | 0 (0.0)        | 0 (0.0)         | -       | 1 (2.0)        | 0 (0.0)        | >0.9999 |
| **Unsolicited adverse events within 28 days** |                 |                 |         |                |                |         |
| Total            | 4 (4.2)        | 5 (4.9)         | >0.9999 | 6 (11.8)       | 3 (6.0)        | 0.4874  |
| Fever            | 1 (1.0)        | 0 (0.0)         | 0.4848  | 0 (0.0)        | 0 (0.0)        | -       |
| Fatigue          | 0 (0.0)        | 1 (1.0)         | >0.9999 | 0 (0.0)        | 0 (0.0)        | -       |
| Muscle Pain      | 1 (1.0)        | 0 (0.0)         | 0.4848  | 1 (2.0)        | 0 (0.0)        | >0.9999 |
| Arthritis        | 0 (0.0)        | 1 (1.0)         | >0.9999 | 1 (2.0)        | 0 (0.0)        | >0.9999 |
| Limbs pain       | 0 (0.0)        | 1 (1.0)         | >0.9999 | 0 (0.0)        | 0 (0.0)        | -       |
| Diarrhea         | 0 (0.0)        | 1 (1.0)         | >0.9999 | 1 (2.0)        | 0 (0.0)        | >0.9999 |
| Oral ulcer       | 1 (1.0)        | 0 (0.0)         | 0.4848  | 0 (0.0)        | 0 (0.0)        | -       |
| Nasopharyngitis  | 1 (1.0)        | 0 (0.0)         | 0.4848  | 0 (0.0)        | 0 (0.0)        | -       |
| Dizziness        | 1 (1.0)        | 0 (0.0)         | 0.4848  | 0 (0.0)        | 0 (0.0)        | -       |
| Allergic rhinitis| 0 (0.0)        | 1 (1.0)         | >0.9999 | 0 (0.0)        | 0 (0.0)        | -       |
| Back pain        | 0 (0.0)        | 0 (0.0)         | -       | 1 (2.0)        | 0 (0.0)        | >0.9999 |
| Disc herniation  | 0 (0.0)        | 0 (0.0)         | -       | 0 (0.0)        | 1 (2.0)        | 0.4951  |
| Lesion           | 0 (0.0)        | 0 (0.0)         | -       | 1 (2.0)        | 1 (2.0)        | >0.9999 |
| Toothache        | 0 (0.0)        | 0 (0.0)         | -       | 0 (0.0)        | 1 (2.0)        | 0.4951  |
| Runny nose       | 0 (0.0)        | 0 (0.0)         | -       | 1 (2.0)        | 0 (0.0)        | >0.9999 |

Data are n (%). n = number of participants. % = proportion of participants. Any = all the participants with any grade adverse reactions or event. The analysis was based on the intervention modified intent-to-treat cohort.
Extended Data Table 2 | Neutralizing antibodies to wild-type SARS-CoV-2 and delta variant before and after a heterogeneous or homologous boost vaccination

|                         | Group A: two doses primed+ Convivieda (n=96) | Group B: two doses primed+ CoronaVac (n=102) | GMT ratio* (Group A/ Group B) | P value | Group C: one dose primed+ Convivieda (n=51) | Group D: one dose primed+ CoronaVac (n=50) | GMT ratio* (Group C/ Group D) | P value |
|-------------------------|---------------------------------------------|---------------------------------------------|-------------------------------|---------|---------------------------------------------|---------------------------------------------|-------------------------------|---------|
| Wild-type: Day 0        |                                             |                                             |                               |         |                                             |                                             |                               |         |
| GMT                     | 2.5 (2.3, 2.7)                              | 2.2 (2.1, 2.3)                              | -                             | 0.0119  | 2.1 (2.0, 2.3)                              | 2.1 (2.0, 2.1)                              | -                             | 0.4876  |
| Day 14                  |                                             |                                             |                               |         |                                             |                                             |                               |         |
| GMT                     | 197.4 (167.7, 232.4)                        | 33.6 (28.3, 39.8)                          | 5.9 (4.5, 7.7)                | <0.0001 | 54.4 (37.9, 78.0)                          | 12.8 (9.3, 17.5)                           | 4.3 (2.5, 7.3)                | <0.0001 |
| Seroconversion          | 100.0 (96.2, 100.0)                         | 97.1 (91.6, 99.4)                          | -                             | 0.2468  | 96.1 (88.5, 99.5)                          | 75.5 (61.1, 86.7)                          | -                             | 0.0030  |
| GMFI                    | 78.3 (68.4, 92.4)                           | 15.2 (12.8, 17.9)                          | -                             | <0.0001 | 25.7 (18.0, 36.9)                          | 6.2 (4.8, 8.4)                            | -                             | <0.0001 |
| Wild-type: Day 28       |                                             |                                             |                               |         |                                             |                                             |                               |         |
| GMT                     | 150.3 (128.8, 175.7)                        | 35.3 (29.4, 42.4)                          | 4.3 (3.2, 5.6)                | <0.0001 | 49.6 (35.1, 70.2)                          | 10.6 (8.3, 13.5)                           | 4.7 (2.9, 7.6)                | <0.0001 |
| Seroconversion          | 100.0 (96.2, 100.0)                         | 97.0 (91.5, 99.4)                          | -                             | 0.2466  | 96.0 (89.2, 100.0)                         | 77.6 (63.4, 88.2)                          | -                             | 0.0021  |
| GMFI                    | 59.5 (50.9, 69.6)                           | 15.9 (13.2, 19.1)                          | -                             | <0.0001 | 23.4 (16.8, 33.1)                          | 5.2 (4.1, 6.5)                            | -                             | <0.0001 |
| Delta B.1.617.2: Day 0   |                                             |                                             |                               |         |                                             |                                             |                               |         |
| GMT                     | 2.2 (2.0, 2.3)                              | 2.1 (2.0, 2.2)                              | -                             | 0.7818  | 2.0 (2.0, 2.1)                              | 2.0 (-)                                   | -                             | 0.3265  |
| Day 14                  |                                             |                                             |                               |         |                                             |                                             |                               |         |
| GMT                     | 55.0 (44.5, 68.0)                           | 8.2 (6.6, 10.1)                            | 6.7 (4.9, 9.5)                | <0.0001 | 10.6 (7.1, 16.5)                           | 3.6 (2.9, 4.4)                             | 3.0 (1.8, 5.2)                | <0.0001 |
| Seroconversion          | 95.8 (89.7, 98.9)                           | 66.9 (46.7, 66.6)                          | -                             | <0.0001 | 56.9 (42.3, 70.7)                          | 26.5 (15.0, 41.1)                          | -                             | 0.0021  |
| GMFI                    | 25.6 (20.6, 31.8)                           | 3.9 (3.1, 4.9)                             | -                             | <0.0001 | 5.3 (3.5, 8.1)                             | 1.8 (1.4, 2.2)                            | -                             | <0.0001 |

Data are GMT (95% CI), number of participants (%), 95% CI). n= the number of participants included the intervention modified intention-to-treat cohort. The P values are the results of comparison between the two treatment groups. Measurements were on day 0 were taken immediately before vaccination. GMT = geometric mean titer. GMFI = geometric mean fold increase. *The non-inferiority bound = 0.67. The lower limit of 95% CI of GMT ratio of > 0.67, indicated that the GMTs of the heterogeneous group was noninferior to that of the homologous group.
## Extended Data Table 3 | GMT of neutralizing antibodies against SARS-CoV-2 stratified by the pre-existing anti-Ad5 neutralizing antibody titers

|                   | Pre-existing anti-Ad5 neutralizing antibody titer ≤ 1:200 | Pre-existing anti-Ad5 neutralizing antibody titer > 1:200 | P value |
|-------------------|-----------------------------------------------------------|-----------------------------------------------------------|---------|
| GMT               | n                                                         | n                                                         |         |
| Group A           | 27 (218.9, 387.0)                                         | 69 (140.2, 205.1)                                         | 0.0027  |
| (two doses primed+ Convidecia) |                                                   |                                                           |         |
| Group C           | 19 (31.4, 120.9)                                          | 32 (32.4, 78.5)                                           | 0.5921  |
| (one dose primed+ Convidecia) |                                                  |                                                           |         |

Data are GMT (95% CI); n = the number of participants included the intervention modified intention-to-treat cohort. The p values are the results of comparison between pre-existing anti-Ad5 neutralizing antibody titer ≤ 1:200 and pre-existing anti-Ad5 neutralizing antibody titer > 1:200. GMT = geometric mean titer.
Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- [ ] The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- [ ] A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- [ ] The statistical test(s) used AND whether they are one- or two-sided
  - Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- [ ] A description of all covariates tested
- [ ] A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- [ ] A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) and variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- [ ] For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted
  - Give P values as exact values whenever suitable.
- [ ] For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- [ ] For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- [ ] Estimates of effect sizes (e.g. Cohen’s d, Pearson’s r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection
Data collected in the electronic case report form, and was done by using CIMS-EDC, V5.1.5 (Chengdu, China).

Data analysis
Statistical analyses were done by using SAS (version 9.4) or GraphPad Prism 8.0.1. Sample size calculation was performed by using Power Analysis and Sample Size (PASS 11) software (version 11.0.7). No custom codes have been developed in the study.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The study protocol and statistical analysis plan (SAP) are available in the Supplementary Information file. In order to protect participants’ confidentiality, the individual participant data that underlie the results reported in this article (text, tables, figures and extended data) will only be shared after de-identification. Researchers who provide a scientifically sound proposal will be allowed to access to the de-identified individual participant data. Since this clinical trial is ongoing, the data will be available for request. The raw data will be available immediately following publication till one year after the publication. One month after the completion of the study (anticipated in January 2022). Proposals should be directed to jszf@cvip.sina.com or cw0226@foxmail.com.
Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences
- Behavioural & social sciences
- Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-list.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size
The sample size calculation was based on the hypothesis on a boost vaccination following the two-dose of inactivated vaccine regimen [group A and B], and performed by using Power Analysis and Sample Size (PASS) 11 software (version 11.0.7). We assumed that the GMT of neutralizing antibodies was about 1:40 at baseline before receiving the booster immunization (i.e. three to six months after receiving two doses of inactivated vaccines). After the boost vaccination, the GMTs were expected to reach 1:80 for those receiving a homologous dose of CoronaVac, and 1:160 for those receiving a or a heterologous dose of Convidexia at days 14. Equal standard deviation of GMTs of 4 was estimated for both groups. A sample size of 100 per treatment group would provide over 99% power to identify a non-inferiority in log-transformed postvaccination GMTs of neutralizing antibodies at a non-inferiority bound of 0.67, and at least 90% power to detect a superiority of heterologous at one-side 0.025 significance level. The probability to observe a particular adverse event with an incidence of 2% at least once in 100 participants in each group was 86.7%. In addition, a heterologous vaccination following one dose of inactivated vaccine (group C and D) was also explored, but was not considered as primary targeted immunization schedule, for which the power was not pre-calculated and may result in an under-powered comparison. However, a post-hoc power calculation showed that the sample size of 50 individuals per group for the two-dose regimen cohort could provide a power over 99% to show the difference between the heterologous and the homologous groups.

Data exclusions
No data were excluded from the analysis.

Replication
This is an interim report of an ongoing human clinical trial. There was no attempt at replication of the study findings.

Randomization
We used an interactive web-based response randomization system stratified according to the number of priming doses the participants have received. Eligible participants who completed the two-dose schedule of CoronaVac in the past 3–6 months were randomly assigned at a 1:1 ratio to receive a booster dose of Convidexia (group A, heterologous boost dose) or CoronaVac (group B, homologous boost dose). While, participants who were primed with one dose of CoronaVac in the past 1–3 months were randomized in a 1:1 ratio to receive a second dose of Convidexia (group C, heterologous dose) or CoronaVac (group D, homologous dose). The randomization lists were generated by an independent statistician using SAS (version 9.4).

Blinding
We masked investigators, laboratory staff, and outcome assessors to the allocation of treatment groups, but not to the three-dose or two-dose regimen. Since the vials and syringes of Convidexia and CoronaVac were different, designated unblinded personnel were responsible for the vaccine preparation and administration. The original labels marked on the syringes for injection were concealed by a label of randomisation number before use. The unblinded personnel did not participate in any other process of the trial and were forbidden to reveal the identity of the study vaccines to any other investigators.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

| n/a | Involved in the study |
|-----|-----------------------|
| ☑ | Antibodies |
| ☑ | Eukaryotic cell lines |
| ☑ | Palaeontology and archaeology |
| ☑ | Animals and other organisms |
| ☑ | Human research participants |
| ☑ | Clinical data |
| ☑ | Dual use research of concern |

Methods

| n/a | Involved in the study |
|-----|-----------------------|
| ☑ | ChIP-seq |
| ☑ | Flow cytometry |
| ☑ | MRI-based neuroimaging |

Eukaryotic cell lines

Policy information about cell lines

Cell line source(s)
Vero-E6 cells (National collection of authenticated cell cultures, National Academy of Science, China); A549 cell (American Strain Preservation Center, Maryland)
Human research participants

Policy information about studies involving human research participants

Population characteristics
The demographic characteristics of participants are shown in Table 1. At enrollment, 27.1 and 11.8% of the participants who completed two doses in the last 3 to 6 months, and 5.9 and 4.0% of those who received one dose in the last 1 to 2 months showed positive neutralizing antibody against SARS-CoV-2 in serum at baseline before receiving a boost vaccination.

Recruitment
We recruited participants from one clinic site in Lianshi County, Jiangsu Province. Healthy participants, male or female, aged between 18 and 59 years, who have completed one dose priming of CoronaVac in the past 1–3 months or two-dose priming of CoronaVac in the past 3–6 months were recruited for screening of eligibility. Participants with a previous clinical or virologic COVID-19 diagnosis or SARS-CoV-2 infection, and women with positive urine pregnancy test results were excluded from this study. Detailed inclusion and exclusion criteria are shown in the protocol. The baseline neutralizing antibody level against SARS-CoV-2 was slightly higher in group A compared with that in group B, which may cause an upward bias in terms of the neutralizing antibody levels after the boosting.

Ethics oversight
The trial was reviewed and approved by the Research Ethics Committee of the Jiangsu Provincial Center of Disease Control and Prevention, and no protocol change was made after the initial of the study.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Clinical data

Policy information about clinical studies
All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.

Clinical trial registration
This trial was prospectively registered with ClinicalTrials.gov (NCT 04892459).

Study protocol
The protocol has been submitted.

Data collection
Between May 25 and 26, 2021, we recruited 302 participants. All eligible participants were observed at the clinic for 30 minutes after the vaccination for any immediate vaccine-associated reactions, and then were instructed to keep a daily record of any solicited or unsolicited adverse events for the next 14 days. Serious adverse events self-reported by participants were documented till months 6. 20ml blood sample was collected from each participant at baseline before, and at 14, 28 days and 6 months after receiving the booster dose.

Outcomes
Primary endpoints: The incidence of adverse reactions in each group within 28 days after the boost vaccination; Neutralising antibodies to live SARS-CoV-2 (GMT) at after the boost vaccination 14 days.
Secondary endpoints: Incidence of solicited adverse reactions and unsolicited adverse reactions at 0–28 days after the boost vaccination; Incidence of serious adverse events (SAE); The anti-SARS-CoV-2 S and N protein specific antibody (ELISA) at Day14, Day28 and Month 6 after the boost vaccination in each group; The neutralising antibodies to live SARS-CoV-2 at Day28 and Month 6 after the boost vaccination in each group; The levels of IFN-γ, TNF-α, IL-5, IL-4, IL-13, and Th1/Th2 cytokine secreted by specific T cells in each group at the Day14 after the boost vaccination; Exploratory endpoints: Isotypes of binding antibodies IgG against SARS-CoV-2 S protein after the boost vaccination; Cross neutralizing of the antibodies to variants of SARS-CoV-2; Activation of immune cells and antibody spectrum of B cells, T cells.